CENTRAL ASIAN JOURNAL OF NEPHROLOGY
Review Article
Apr 02, 2026 2 2

IgA Nephropathy: Current Treatment Strategies and Perspectives on Targeted Therapy

Gulnar Chingayeva 1 * ,
Dina Karibayeva 2,
Assel Issenova 3,
Abay Shepetov 1,
Nagima Mustapayeva 1,
Nazym Nigmatullina 1,
Kairat Kabylbayev 1,
Elmira Alimzhanova 1,
Marzhan Shepetova 1,
Zhadira Abiyeva 1,
Zhuldyz Baidauletova 4,
Nazym Dauletbayeva 1,
Arina Yespotayeva 1
1 Department of Nephrology, S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan2 Department of General Medical Practice, Kazakh-Russian Medical University, Almaty, Kazakhstan3 Department of Gynecology, National Scientific Medical Center, Astana, Kazakhstan4 Department of Internal Medicine of the Higher School of Medicine and the Faculty of Medicine and Health, Al-Farabi Kazakh National University, Almaty, Kazakhstan* Corresponding Author
Central Asian Journal of Nephrology, 2(1), 2026, cajn013, https://doi.org/10.63946/cajn/18302
Publication date: Apr 02, 2026
Full Text (PDF)

ABSTRACT

Background: Immunoglobulin A nephropathy is among the most commonly observed glomerular disorders. Its development is associated with immune dysfunction, which initiates a cascade of pathological changes within the glomeruli. The clinical course can range from minimal urinary abnormalities to progressive renal impairment, potentially culminating in end-stage kidney disease. Despite considerable advances in understanding its pathogenesis, optimal therapeutic strategies remain an active focus of scientific investigation.
Aim: To assess current and emerging therapeutic strategies for IgA nephropathy, with an emphasis on efficacy, safety, and the potential of targeted agents addressing key pathogenic pathways.
Methods: We conducted a narrative review of recent literature in PubMed, Scopus, Web of Science, and eLIBRARY databases, focusing on publications from the last decade. Studies published in English and Russian that reported results from clinical trials or meta-analyses on therapeutic interventions for IgA nephropathy were included. Search terms included «IgA nephropathy», «treatment», «targeted therapy», «new therapies», «immunosuppressants», and «clinical trials». Priority was given to randomized controlled trials and studies with high-quality evidence, though relevant observational data were also considered.
Results: Key studies identified included 52 publications, among which 20 were randomized clinical trials and a systematic review. Corticosteroid therapy remains a cornerstone of treatment but is limited by significant adverse effects. Recent therapeutic developments in IgA nephropathy have focused on interventions that selectively target inflammatory and immune pathways involved in disease progression. Certain novel agents aimed at modulating immune signaling or addressing pathogenic plasma cells have shown potential to reduce proteinuria and stabilize renal function. Early-phase clinical investigations indicate promising efficacy and manageable safety profiles, suggesting these approaches may represent important advances in disease management.
Conclusions: Recent progress in targeted and immunomodulatory therapies offers new perspectives for personalized treatment of IgA nephropathy. Comprehensive, large-scale randomized studies with extended follow-up are warranted to thoroughly assess the therapeutic potential, safety profile, and optimal positioning of these interventions within future clinical management strategies.

KEYWORDS

IgA Nephropathy Targeted Therapy Budesonide Immunosuppression Complement Inhibition SGLT2 Inhibitors Treatment Narrative Review

CITATION (Vancouver)

Chingayeva G, Karibayeva D, Issenova A, Shepetov A, Mustapayeva N, Nigmatullina N, et al. IgA Nephropathy: Current Treatment Strategies and Perspectives on Targeted Therapy. Central Asian Journal of Nephrology. 2026;2(1):cajn013. https://doi.org/10.63946/cajn/18302
APA
Chingayeva, G., Karibayeva, D., Issenova, A., Shepetov, A., Mustapayeva, N., Nigmatullina, N., Kabylbayev, K., Alimzhanova, E., Shepetova, M., Abiyeva, Z., Baidauletova, Z., Dauletbayeva, N., & Yespotayeva, A. (2026). IgA Nephropathy: Current Treatment Strategies and Perspectives on Targeted Therapy. Central Asian Journal of Nephrology, 2(1), cajn013. https://doi.org/10.63946/cajn/18302
Harvard
Chingayeva, G., Karibayeva, D., Issenova, A., Shepetov, A., Mustapayeva, N., Nigmatullina, N., . . . Yespotayeva, A. (2026). IgA Nephropathy: Current Treatment Strategies and Perspectives on Targeted Therapy. Central Asian Journal of Nephrology, 2(1), cajn013. https://doi.org/10.63946/cajn/18302
AMA
Chingayeva G, Karibayeva D, Issenova A, et al. IgA Nephropathy: Current Treatment Strategies and Perspectives on Targeted Therapy. Central Asian Journal of Nephrology. 2026;2(1), cajn013. https://doi.org/10.63946/cajn/18302
Chicago
Chingayeva, Gulnar, Dina Karibayeva, Assel Issenova, Abay Shepetov, Nagima Mustapayeva, Nazym Nigmatullina, Kairat Kabylbayev, Elmira Alimzhanova, Marzhan Shepetova, Zhadira Abiyeva, Zhuldyz Baidauletova, Nazym Dauletbayeva, and Arina Yespotayeva. "IgA Nephropathy: Current Treatment Strategies and Perspectives on Targeted Therapy". Central Asian Journal of Nephrology 2026 2 no. 1 (2026): cajn013. https://doi.org/10.63946/cajn/18302
MLA
Chingayeva, Gulnar et al. "IgA Nephropathy: Current Treatment Strategies and Perspectives on Targeted Therapy". Central Asian Journal of Nephrology, vol. 2, no. 1, 2026, cajn013. https://doi.org/10.63946/cajn/18302

REFERENCES

  1. Floege J, Bernier-Jean A, Barratt J, Rovin B. Treatment of patients with IgA nephropathy: a call for a new paradigm. Kidney Int. 2025;107(4):640-651. https://doi.org/10.1016/j.kint.2025.01.014
  2. Kwon CS, Daniele P, Forsythe A, Ngai C. A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy. JHEOR. 2021;8(2):36-45. https://doi.org/10.36469/001c.26129
  3. Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem M, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727-738. https://doi.org/10.2215/cjn.0000000000000135
  4. Grabe DW. Preventing Progression in IgA Nephropathy: A Managed Care Focus on Emerging Therapies. AJMC. 2023;29(3):31-43. https://doi.org/10.37765/ajmc.2023.89344
  5. Kwon CS, Daniele P, Forsythe A, Ngai C. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin a nephropathy. JHEOR. 2021;8(2):36-45. https://doi.org/10.36469/jheor.2021.26129
  6. Kiryluk K, Freedberg DE, Radhakrishnan J, Segall L, Jacobson JS, Mathur M, Mohan S, Neugut AI. Global Incidence of IgA Nephropathy by Race and Ethnicity: A Systematic Review. Kidney360. 2023;4(8):1112-1122. https://doi.org/10.34067/KID.0000000000000165
  7. Lee M, Suzuki H, Nihei Y, Matsuzaki K, Suzuki Y. Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis. Clin Kidney J. 2023;16(Suppl 2):1-8. https://doi.org/10.1093/ckj/sfad199
  8. Rodrigues JC, Haas M, Reich HN. IgA Nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677-686. https://doi.org/10.2215/CJN.07420716
  9. Thompson A, Carroll K, Lesley I, Floege J, Perkovic V, Boyer-Suavet S, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469–481. https://doi.org/10.2215/cjn.08600718
  10. Cattran DC, Floege J, Coppo R. Evaluating progression risk in patients with immunoglobulin A nephropathy. Kidney Int Rep. 2023;8(12):2515–28. https://doi.org/10.1016/j.ekir.2023.09.020
  11. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025;108(4S):1–71. https://kdigo.co/KDIGO-IgAN-IgAV-Guideline
  12. Duan ZY, Zhang C, Chen XM, Cai GY. Blood and urine biomarkers of disease progression in IgA nephropathy. Biomark Res. 2024;12(1):72. https://doi.org/10.1186/s40364-024-00619-4
  13. Wieliczko M, Nazarewski S, Gałązka Z, Jolanta S. Recurrence of glomerulonephritis after kidney transplantation - experience of one center from 2020 to 2023. Transplant Proc. 2024;56(4):789–92. https://doi.org/10.1016/j.transproceed.2024.03.015
  14. Lim WH, Shingde M, Wong G. Recurrent and de novo glomerulonephritis after kidney transplantation. Front Immunol. 2019;10:1944. https://doi.org/10.3389/fimmu.2019.01944
  15. Ramsawak S, Cohen S, Linares A, Cavanaugh C. IgA nephropathy: update on pathogenesis and treatment. Cleve Clin J Med. 2025;92(6):373-383. https://doi.org/10.3949/ccjm.92a.24105
  16. Zhou XJ. Immunoglobulin A Nephropathy: Molecular Pathogenesis and Targeted Therapy. MedComm. 2025;6(9):e70382. https://doi.org/10.1002/mco2.70382
  17. Rizk DV, Saha MK, Hall S, Novak L, Brown R, Huang Z, et al. Glomerular immunodeposits of patients with IgA nephropathy are enriched for IgG autoantibodies specific for galactose-deficient IgA1. Clin J Am Soc Nephrol. 2019;30(10):2017–2026. https://doi.org/10.1681/asn.2018111156
  18. Chiu YL, Lin WC, Shu KH, Fang YW, Chang FC, Chou YH, Wu CF, Chiang WC, Lin SL, et al. Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA1 Antibody in IgA Nephropathy Patients. Front Immunol. 2021;12:638309. https://doi.org/10.3389/fimmu.2021.638309
  19. Gleeson PJ, M O'Shaughnessy M, Barratt J. IgA nephropathy in adults - treatment standard. Nephrol Dial Transplant. 2023;38(11):2464–2473. https://doi.org/10.1093/ndt/gfad146
  20. Barratt J, Lafayette RA, Floege J. Therapy of IgA nephropathy: time for a paradigm change. Front Med (Lausanne). 2024;11:1461879. https://doi.org/10.3389/fmed.2024.1461879
  21. Zhao H, Li Y, Sun J, Xu G, Wang C, Zhou S, et al. Immunosuppression versus Supportive Care on Kidney Outcomes in IgA Nephropathy in the Real-World Setting. CJASN. 2024;18(9):1186-1194. https://doi.org/10.2215/CJN.0000000000000215
  22. El Karoui K, Fervenza FC, De Vriese AS. Treatment of IgA Nephropathy: A Rapidly Evolving Field. JASN. 2024;35(1):103-116. https://doi.org/10.1681/ASN.0000000000000242
  23. Petrou D, Kalogeropoulos P, Liapis G, Lionaki S. IgA Nephropathy: Current Treatment and New Insights. Antibodies. 2023;12(40):1-14. https://doi.org/10.3390/antib12020040
  24. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):1–276. https://doi.org/10.1016/j.kint.2021.05.021
  25. Floege J, Barratt J, Cook HT, Noronha IL, Reich HN, Suzuki Y, et al. Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). (No DOI/URL provided)
  26. Yu G, Cheng J, Jiang Y, Li H, Li X, Chen J. Intensive Systolic Blood Pressure Lowering and Kidney Disease Progression in IgA Nephropathy: A Cohort Study. Front Med (Lausanne). 2022;9:813603. https://doi.org/10.3389/fmed.2022.813603
  27. Noor SM, Abuazzam F, Mathew R, Zhang Z, Abdipour A, Norouzi S. IgA nephropathy: a review of existing and emerging therapies. Front Nephrol. 2023;3:1175088. https://doi.org/10.3389/fneph.2023.1175088
  28. Vivarelli M, Samuel S, Coppo R, Barratt J, Bonilla-Felix M, Haffner D, et al. IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis. Pediatr Nephrol. 2024;40(2):533–569. https://doi.org/10.1007/s00467-024-06502-6
  29. Shima Y, Mukaiyama H, Tanaka Y, Shimabukuro W, Nozu K, Kaito H, et al. Factors related to recurrence of proteinuria in childhood IgA nephropathy. Pediatr Nephrol. 2024;39(2):463–71. https://doi.org/10.1007/s00467-023-06116-4
  30. Peruzzi L, Coppo R. Expected and verified benefits from old and new corticosteroid treatments in IgA nephropathy: from trials in adults to new IPNA-KDIGO guidelines. Pediatr Nephrol. 2025;40(7):2121–2131. https://doi.org/10.1007/s00467-025-06725-1
  31. Barratt J, Lafayette RA, Rovin BH, Fellström B. Budesonide delayed-release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy. Expert Rev Clin Immunol. 2022;19:699-710. https://doi.org/10.1080/1744666X.2023.2206119
  32. Xue C, Yu S, Gou W, Xu Y, Yang L, Dai B. Precision Treatment of IgA Nephropathy Based on a New Framework: Angiorenal Protection, Immunity Inhibition, B-Cell/Plasma-Cell Modulation, and Complement Inhibition. Kidney Dis. 2025;11(1):154–159. https://doi.org/10.1159/000544998
  33. Sevillano AM, Gutiérrez E, Yuste C, Cavero T, Mérida E, Rodríguez P, et al. Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol. 2017;28(10):3089–99. https://doi.org/10.1681/asn.2017010108
  34. Weng M, Lin J, Chen Y, Zhang X, Zou Z, Chen Y, et al. Time-Averaged Hematuria as a Prognostic Indicator of Renal Outcome in Patients with IgA Nephropathy. J Clin Med. 2022;11(22):6785. https://doi.org/10.3390/jcm11226785
  35. Louise O, Rona S, Alan SD, Jonathan B, Howard T, Moin S. Bridging the 13-Year Evidence Gap: A Time for Age-Inclusive Research. JASN. 2024;35(4):502-504. https://doi.org/10.1681/ASN.0000000000000301
  36. Mathur M, Sahay M, Pereira BJG, Rizk DV. State-of-Art Therapeutics in IgA Nephropathy. Indian J Nephrol. 2024;34:417-30. https://doi.org/10.25259/ijn_319_23
  37. Kim J, Kamal F, Yeung B, Lafayette R. How should we best manage the consequences of nephron loss in IgAN? Nephrol Dial Transplant. 2025;gfaf225. https://doi.org/10.1093/ndt/gfaf225
  38. Momoniat T. ACE inhibitors and ARBs: Managing potassium and renal function. Cleve Clin J Med. 2019;86(9):601-607. https://doi.org/10.3949/ccjm.86a.18024
  39. Zeier M. ACE Inhibitors and ARB in Chronic Kidney Disease: What Has to Be Considered. Dtsch Med Wochenschr. 2018;143(12):880-885. https://doi.org/10.1055/a-0549-9662
  40. Stamellou E, Seikrit C, Tang SCW, Boor P, Tesař V, Floege J, et al. IgA nephropathy. Nat Rev Dis Primers. 2023;9(1):67. https://doi.org/10.1038/s41572-023-00476-9
  41. Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022;327(19):1888–98. https://doi.org/10.1001/jama.2022.5368
  42. Glassock RJ. An expert opinion on current and future treatment approaches in IgA nephropathy. Adv Ther. 2025;42(6):2545–58. https://pubmed.ncbi.nlm.nih.gov/40220242
  43. Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023;402(10405):859–70. https://doi.org/10.1016/s0140-6736(23)01554-4
  44. Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402:2077-2090. (No DOI provided)
  45. Wimbury D, Muto M, Bhachu JS, Scionti K, Brown J, Molyneux K, et al. Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial. Kidney Int. 2024;105(2):381–8. https://doi.org/10.1016/j.kint.2023.11.003
  46. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. https://doi.org/10.1056/nejmoa2024816
  47. Wheeler DC, Toto RD, Stefánsson BV, Jongs N, Chertow GM, Greene T, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100(1):215–24. https://doi.org/10.1016/j.kint.2021.03.033
  48. Zurowska A. Game Changers in IgA Nephropathy. EMJ. 2025;13(1):23-27. https://doi.org/10.33590/emjnephrol/YKIN5558
  49. Lerma EV, Batuman V. Diabetes and Kidney Disease. Second Edition. 2022. p.21-37. (No DOI provided)
  50. Konda R, Rajasekaran A, Rizk DV. What do clinical trials teach us about the pathophysiology of human IgA nephropathy? NDT. 2025. https://doi.org/10.1093/ndt/gfaf144
  51. Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023;401(10388):1584–94. https://doi.org/10.1016/s0140-6736(23)00569-x
  52. Selvaskandan H, Jhaveri KD, Rizk DV. Primary IgA Nephropathy: New Insights and Emerging Therapies. Adv Kidney Dis Health. 2024;31(3):180-193. https://doi.org/10.1053/j.akdh.2024.04.002
  53. Vecchio LD, Allinovi M, Comolli S, Peiti S, Rimoldi C, Locatelli F. Drugs in Development to Treat IgA Nephropathy. Drugs. 2024;84:503-525. (No DOI provided)
  54. El Karoui K, Fervenza FC, De Vriese AS. Treatment of IgA Nephropathy: A Rapidly Evolving Field. JASN. 2024;35(1):103–116. https://doi.org/10.1681/ASN.0000000000000242
  55. Wendt R, Sobhani A, Diefenhardt P, Trappe M, Völker LA. An Updated Comprehensive Review on Diseases Associated with Nephrotic Syndromes. Biomedicines. 2024;12(10):2259. https://doi.org/10.3390/biomedicines12102259
  56. FDA. Letter approving Fabhalta (iptacopan) for primary IgA nephropathy (NDA 218276/S‑001). Silver Spring, MD: FDA; 2024 [cited 2025 Nov 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/218276Orig1s001ltr.pdf
  57. Coppo R, Troyanov S, Camilla R, et al. Pathogenesis and therapy of IgA nephropathy: Focus on complement activation. J Nephrol. 2022;35:123–135. (No DOI provided)
  58. Floege J, Barratt J, Tang SCW. IgA nephropathy: recent developments and therapeutic strategies. Lancet. 2019;393:2287–2298. (No DOI provided)
  59. Bo S, Sun A, Yang W, Wang X, Liu L. Targeted therapeutic options based on the pathogenesis of IgA nephropathy. NDT. 2025;gfaf167. https://doi.org/10.1093/ndt/gfaf167
  60. Bryce B, Sean B. New therapies for immunoglobulin A nephropathy: what's the standard of care in 2023? Nephrol Hypertens. 2024;33(3):311-317. (No DOI provided)
  61. Willcocks L. ALIGNing the treatment of IgA nephropathy: Reducing proteinuria with endothelin A receptor inhibition. Med. 2025;6(10):100564. https://doi.org/10.1016/j.medj.2024.11.017
  62. Perkovic V, Barratt J, Rovin B, Kashihara N, Maes B, Zhang H, et al. Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N Engl J Med. 2025;392(6):531–43. https://doi.org/10.1056/nejmoa2410316
  63. Praga M, Caravaca-Fontán F, Da Silva I, Fernández-Juárez G, Gutiérrez E, Sevillano AM, Trimarchi H. Tailored management strategies for IgA nephropathy based on clinical presentations. NDT. 2025;40(5):874-883. https://doi.org/10.1093/ndt/gfae289
  64. Cheung CK, Barratt J, Liew A, Zhang H, Tesar V, Lafayette R. The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies. Front Nephrol. 2024;3:1346769. https://doi.org/10.3389/fneph.2023.1346769
  65. Han HS, Lubetzky ML, Anandasivam NS, Cox RA, Lee BK. Recurrent Immunoglobulin A Nephropathy after Kidney Transplant - An Updated Review. Transplantology. 2023;4(3):161-177. https://doi.org/10.3390/transplantology4030016
  66. Kooienga L, Lo J, Lee EY, Kim SG, Thomas H, Workeneh B, et al. Zigakibart demonstrates clinical safety and efficacy in a phase 1/2 trial of healthy volunteers and patients with IgA nephropathy. Kidney Int. 2025;108(3):445–54. https://doi.org/10.1016/j.kint.2025.05.006
  67. Lv J, Liu L, Hao C, Li G, Fu P, Xing G, et al. Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep. 2023;8(3):499–506. https://doi.org/10.1016/j.ekir.2022.12.014
  68. Barratt J, Tumlin J, Suzuki Y, Kao A, Aydemir A, Pudota K, et al. Randomized phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria. Kidney Int Rep. 2022;7(8):1831–41. https://doi.org/10.1016/j.ekir.2022.05.017
  69. Lafayette R, Barbour S, Israni R, Wei X, Eren N, Floege J, et al. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int. 2024;105(6):1306–15. https://doi.org/10.1016/j.kint.2024.03.012
  70. Floege J, Latus J, O’Shaughnessy M. Revolutionising IgA Nephropathy Care in the Era of Precision Medicine: Diagnostic Approaches, Evolving Guidelines, and Emerging Therapies. EMJ Nephrol. 2025;13(S1):2-10. https://doi.org/10.33590/emjnephrol/KZVG1889
  71. Barratt J, Liew A, Yeo SC, Fernström A, Barbour SJ, et al. Phase 2 trial of cemdisiran in adult patients with IgA nephropathy: a randomized controlled trial. Clin J Am Soc Nephrol. 2024;19(4):452–62. https://doi.org/10.2215/cjn.0000000000000384
  72. Barratt J, Liew A, Yeo SC, Fernström A, Barbour SJ, Sperati CJ, et al. Efficacy and safety of ravulizumab in IgA nephropathy: a phase 2 randomized double-blind placebo-controlled trial. Clin J Am Soc Nephrol. 2025;36(4):645–56. https://doi.org/10.2215/cjn.0000000000000384
  73. Lin L, Ren H, Li X, Xie J, Chen N. Prospective pilot study of plasma cell-targeted therapy with bortezomib in refractory IgA nephropathy. Kidney Int Rep. 2025;10(9):3023–31. https://doi.org/10.1016/j.ekir.2025.06.006
  74. KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2024;105(Suppl 1):S1–S200. (No DOI provided)
  75. Sethi S, De Vriese AS, Fervenza FC. Acute glomerulonephritis. Lancet. 2022;399(10335):1646-1663. (No DOI provided)
  76. Caster DJ, Abner CW, Walker PD, Wang K, Heo J, Rava AR, Bunke M. Clinicopathological Characteristics of Adult IgA Nephropathy in the United States. Kidney Int Rep. 2023;8(9):1792-1800. https://doi.org/10.1016/j.ekir.2023.06.016
  77. Chen H, Li X, Wu Y, Fan L, Tian G. Pregnancy-induced complications in IgA nephropathy: a case report. Medicine (Baltimore). 2018;97(15):e0470. https://doi.org/10.1097/md.0000000000010470
  78. Shima H, Doi T, Okamoto T, Inoue T, Tashiro M, Wariishi S, et al. Successful treatment of nephrotic syndrome due to pregnancy-related crescentic IgA nephropathy: a case report. BMC Nephrol. 2023;24(1):92. https://doi.org/10.1186/s12882-023-03152-y
  79. Fabhalta (Iptacopan) [prescribing information]. U.S. Food and Drug Administration; 2025. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/218276Orig1s000Lbl.pdf
  80. Ito S, et al. Drug therapy and lactation: clinical pharmacology of drugs in breast milk. Clin Pharmacokinet. 2020;59:121–143. (No DOI provided)
  81. Rovin BH, et al. Management of IgA nephropathy: recent advances. Kidney Int. 2022;101:799–812. (No DOI provided)
  82. Drugs.com. Iptacopan and breastfeeding. Available from: https://www.drugs.com/pregnancy/iptacopan.html

LICENSE

Creative Commons License
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.